Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTX-003
- Development stage
- Preclinical
- Lead developer
- Ceria Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
CTX-003 is a preclinical-stage RNA therapeutic developed by Ceria Therapeutics for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. It is an orally administered formulation consisting of a microRNA-146a (miRNA-146a) mimic conjugated to a cerium oxide nanoparticle. The mechanism of action involves the suppression of Interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6), which are key mediators in the TLR4/NF-kB inflammatory signaling pathway. By downregulating these targets, CTX-003 aims to reduce pathological inflammation in the gastrointestinal tract.
02
Targets
IRAK1 (Interleukin-1 receptor-associated kinase 1)TRAF6
Beyond the preview
Go deeper on CTX-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTX-003.